Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIGRANT: FMT and Durvalumab in Stage II-III NSCLC
NCT07247786Phase 2Not yet recruiting
- Sponsor
- Fundación GECP
- Start
- Sep 2026
- Primary completion
- Dec 2031
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic fecal microbiota in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07247786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07247786.